MedTrace Logo

Adjuvant Therapy of Gefitinib (Iressa, ZD1839) in Patients With Resectable Hepatocellular Carcinoma

NCT00282100 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2019-04-16

No results posted yet for this study

Summary

This research is being done to find how soon the liver cancer may come back and whether proteins or genes in tumor, blood or urine can give us clues of early recurrence.

Conditions

Interventions

DRUG

Gefetinib (Iressa)

Sponsors & Collaborators

  • Singapore Cancer Syndicate.

    collaborator UNKNOWN

  • AstraZeneca

    collaborator INDUSTRY

  • Tan Tock Seng Hospital

    lead OTHER

Principal Investigators

  • Alex Chang, M.D. · Tan Tock Seng Hospital

Study Design

Allocation
NA
Purpose
PREVENTION
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-12-31
Primary Completion
2019-09-30
Completion
2019-09-30

Countries

  • Singapore

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00282100 on ClinicalTrials.gov